Endocrine News and Research

RSS

EDMA to endorse the campaign on Hypoparathyroidism

On the occasion of the World Hypoparathyroidism Awareness Day 2011, EDMA, the European Diagnostic Manufacturers Association, highlights the crucial role the In Vitro Diagnostic (IVD) industry can play to effectively testing this rare endocrine condition.

5 Jan 2011

Exposure to persistent organic pollutants alters cortisol level in blood

Karin E Zimmer's PhD research shows that persistent organic pollutants (POPs), such as PCB and mixtures of different POPs, affect the way the adrenal cortex functions and thereby the synthesis of the stress hormone cortisol.

28 Dec 2010

Mylan confirms lawsuit by Shionogi Pharma and CIMA LABS relating to generic Orapred ODT ANDA

Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.

17 Dec 2010

Vertical Health acquires prominent pain journal

Vertical Health, a leading health information company focused on pain management, musculoskeletal diseases and endocrine diseases, is pleased to announce the acquisition of Practical Pain Management, the most prominent pain journal for the practicing pain physician. This acquisition marks the next phase in Vertical Health's mission to serve the health information needs of patients suffering from pain and the physicians who treat them.

17 Dec 2010

BPA exposure reduces quality of womens' eggs retrieved for IVF

A small-scale University of California, San Francisco-led study has identified the first evidence in humans that exposure to bisphenol A (BPA) may compromise the quality of a woman's eggs retrieved for in vitro fertilization (IVF). As blood levels of BPA in the women studied doubled, the percentage of eggs that fertilized normally declined by 50 percent, according to the research team.

16 Dec 2010

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

VIVUS, Inc. today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010. The company also announced that the Endocrine and Metabolic Division of the FDA has granted VIVUS a meeting in the second half of January 2011 to discuss the content of the proposed resubmission.

14 Dec 2010

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

13 Dec 2010

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.

13 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium

The long-awaited results of the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer, the AZURE trial, will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 8-12.

10 Dec 2010

Oral contraceptives account for less than 1% of estrogen in drinking water

Contrary to popular belief, birth control pills account for less than 1 percent of the estrogens found in the nation's drinking water supplies, scientists have concluded in an analysis of studies published on the topic.

9 Dec 2010

Study demonstrates new test for early diagnosis of Turner syndrome

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) has demonstrated a novel and accurate test for early diagnosis of Turner syndrome. Turner syndrome affects one in 1,500 to 2,000 female live births and early diagnosis allows for the timely management of short stature and co-morbid conditions including cardiac and renal problems.

9 Dec 2010

Bisphenol A tainted money and receipts

Bisphenol A (BPA) has been found in many household items and other common objects and is known to be an endocrine disruptor linked to infertility, genital abnormalities, cancer and more. Now it has been detected on ‘cash’. Since BPA is used to make plastic, manufacturers use about 8 billion pounds of BPA that is moulded, cooked or poured into toys, baby products and other merchandise each year. On these products BPA is chemically bonded but it is simply applied in a powdery film to paper, making it easy to rub off with a touch.

8 Dec 2010

Low and high vitamin D levels may increase frailty in older women

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that lower and higher vitamin D levels were associated with an increased likelihood of frailty in older women. Women with vitamin D levels between 20.0 and 29.9 ng/ml were at the lowest risk of frailty.

8 Dec 2010

TOS, OAC call on FDA to address urgent need for obesity treatments

The Obesity Society (TOS) and the Obesity Action Coalition (OAC) today called on the Food and Drug Administration (FDA) to consider the urgent need for more tools to address the obesity epidemic facing more than 93 million Americans as they convene an advisory panel to review a new treatment for obesity.

8 Dec 2010

FDA advisory committee's approval of Contrave for obesity encourages OAC, TOS, ASMBS

The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.

8 Dec 2010

Expansion of newborn screening throws some families on a journey of great uncertainty

Mandatory genetic screening of newborns for rare diseases is creating unexpected upheaval for families whose infants test positive for risk factors but show no immediate signs of the diseases, a new UCLA study warns.

7 Dec 2010

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

In an unprecedented move, chronic fatigue syndrome patients published a half-page ad in The Washington Post today. The ad brings attention to new, HIV-like retroviruses, including XMRV, which have been linked to CFS and aggressive prostate cancer, and have been detected in healthy blood donors.

6 Dec 2010

Event reporting prevents medication errors in primary care: Study

The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.

4 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Endocrine News and Research

EDMA to endorse the campaign on Hypoparathyroidism

Exposure to persistent organic pollutants alters cortisol level in blood

Mylan confirms lawsuit by Shionogi Pharma and CIMA LABS relating to generic Orapred ODT ANDA

Vertical Health acquires prominent pain journal

BPA exposure reduces quality of womens' eggs retrieved for IVF

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium

Oral contraceptives account for less than 1% of estrogen in drinking water

Study demonstrates new test for early diagnosis of Turner syndrome

Bisphenol A tainted money and receipts

Low and high vitamin D levels may increase frailty in older women

TOS, OAC call on FDA to address urgent need for obesity treatments

FDA advisory committee's approval of Contrave for obesity encourages OAC, TOS, ASMBS

Expansion of newborn screening throws some families on a journey of great uncertainty

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

Event reporting prevents medication errors in primary care: Study

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News